-
公开(公告)号:US20230117289A1
公开(公告)日:2023-04-20
申请号:US17798491
申请日:2021-02-23
申请人: KEMPHARM, INC.
发明人: Sven Guenther , Guochen Chi , Travis Mickle
IPC分类号: C07D401/12 , A61K9/48
摘要: The present technology is directed serdexmethylphenidate compounds and methods for synthesizing a compound having the formula
-
公开(公告)号:US11214544B2
公开(公告)日:2022-01-04
申请号:US16604755
申请日:2018-04-12
申请人: KEMPHARM, INC.
发明人: Travis Mickle , Sven Guenther , Sanjib Bera
IPC分类号: C07D221/28 , A61K31/439 , A61K47/54
摘要: The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and/or vitamin compounds chemically conjugated to dextrorphan, (+)-17-methylmorphinan-3-ol), to form novel prodrugs and compositions of dextrorphan.
-
公开(公告)号:US20210253552A1
公开(公告)日:2021-08-19
申请号:US17240181
申请日:2021-04-26
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Guochen Chi
IPC分类号: C07D401/12 , A61K9/00 , C07D211/34 , A61K31/4545 , A61K47/54 , A61K31/4458
摘要: The present technology is directed to d-threo-methylphenidate conjugates and a composition comprising d-threomethylphenidate conjugated to nicotinoyl-L-serine, or salt thereof. The present technology also relates to a composition comprising at least one conjugate of d-methylphenidate having at least two or more chiral centers. The composition is optically active. The present technology additionally relates to oral formulations and pharmaceutical kits comprising at least one d-threo-methylphenidate conjugate.
-
公开(公告)号:US20210130322A1
公开(公告)日:2021-05-06
申请号:US17115425
申请日:2020-12-08
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Guochen Chi
IPC分类号: C07D401/12 , A61K9/00 , C07D211/34 , A61K31/4545 , A61K47/54 , A61K31/4458
摘要: The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and/or unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:US10849981B2
公开(公告)日:2020-12-01
申请号:US16166954
申请日:2018-10-22
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Christal Mickle , Guochen Chi , Jaroslaw Kanski , Andrea K. Martin , Bindu Bera
IPC分类号: A61K47/54 , A61K31/485 , A61K31/167 , C07D491/08 , C07D489/04 , A61K9/20 , A61K47/55 , A61K45/06
摘要: The presently described technology provides methods of treating a patient having moderate to severe pain, narcotic or opioid abuse or narcotic or opioid withdrawal. The presently described methods are carried out by comprising administering to the patient a pharmaceutically effective amount of a composition comprising acetaminophen and benzoate-hydrocodone hydrochloride. The composition has reduced side effects when compared with unconjugated hydrocodone.
-
公开(公告)号:US10584112B2
公开(公告)日:2020-03-10
申请号:US16431275
申请日:2019-06-04
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Guochen Chi
IPC分类号: C07D401/12 , A61K9/00 , C07D211/34 , A61K31/4545
摘要: The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof.
-
7.
公开(公告)号:US20200016272A1
公开(公告)日:2020-01-16
申请号:US16577876
申请日:2019-09-20
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Guochen Chi
IPC分类号: A61K47/54 , A61K9/00 , A61K31/4458
摘要: The present technology is directed to d-threo-methylphenidate conjugates and a composition comprising d-threomethylphenidate conjugated to nicotinoyl-L-serine, or salt thereof. The present technology also relates to a composition comprising at least one conjugate of d-methylphenidate having at least two or more chiral centers. The composition is optically active. The present technology additionally relates to oral formulations and pharmaceutical kits comprising at least one d-threo-methylphenidate conjugate.The pharmaceutical kit may comprise a specified amount of individual doses in a package. Each individual dose in the package may contain a pharmaceutically effective amount of a conjugate of d-threo methylphenidate.
-
8.
公开(公告)号:US20190256522A1
公开(公告)日:2019-08-22
申请号:US16352125
申请日:2019-03-13
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Christal Mickle , Guochen Chi , Jaroslaw Kanski , Andrea K. Martin , Bindu Bera
IPC分类号: C07D489/04 , C07D489/02 , A61K31/485
摘要: Compositions comprising hydrocodone benzoic acid enol ester to form novel prodrugs including hydrocodone benzoic acid enol ester salts, and various polymorphs. Also provided are processes for the preparation of hydrocodone benzoic acid enol ester salts, and various polymorphs.
-
公开(公告)号:US20190192670A1
公开(公告)日:2019-06-27
申请号:US16290496
申请日:2019-03-01
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Guochen Chi , Jaroslaw Kanski , Andrea K Martin , Bindu Bera
IPC分类号: A61K47/55 , A61K47/54 , A61K9/00 , A61K31/485 , A61K31/616 , A61K31/185
CPC分类号: A61K47/55 , A61K9/0019 , A61K9/0043 , A61K9/0053 , A61K31/185 , A61K31/485 , A61K31/616 , A61K31/70 , A61K47/542
摘要: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-α-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
-
公开(公告)号:US10258696B2
公开(公告)日:2019-04-16
申请号:US16054575
申请日:2018-08-03
申请人: KemPharm, Inc.
发明人: Travis Mickle , Sven Guenther , Guochen Chi , Jaroslaw Kanski , Andrea K. Martin , Bindu Bera
IPC分类号: C07D489/02 , A61K31/485 , A61K47/55 , A61K47/54 , A61K9/00 , A61K31/616 , A61K31/185
摘要: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydromorphone (4,5-α-epoxy-3-hydroxy-17-methyl morphinan-6-one) to form novel prodrugs/compositions of hydromorphone. The hydromorphone prodrugs of the present technology have decreased side effects and decreased potential for abuse compared to unconjugated hydromorphone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.
-
-
-
-
-
-
-
-
-